INT693

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1978
Last Reported 2010
Negated 2
Speculated 3
Reported most in Abstract
Documents 46
Total Number 49
Disease Relevance 8.57
Pain Relevance 21.75

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (SST) extracellular region (SST) cell-cell signaling (SST)
Anatomy Link Frequency
neurons 8
somatotrope 6
hypothalamus 6
pituitary 4
plasma 2
SST (Homo sapiens)
Pain Link Frequency Relevance Heat
Somatostatin 250 100.00 Very High Very High Very High
Clonidine 90 100.00 Very High Very High Very High
Enkephalin 31 100.00 Very High Very High Very High
dexamethasone 2 100.00 Very High Very High Very High
Morphine 6 99.98 Very High Very High Very High
Dopamine 8 99.96 Very High Very High Very High
peptic ulcer disease 7 99.84 Very High Very High Very High
carbamazepine 27 99.70 Very High Very High Very High
Serotonin 8 99.70 Very High Very High Very High
Opioid 2 99.68 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pernicious Anemia 8 100.00 Very High Very High Very High
Obesity 56 99.84 Very High Very High Very High
Ulcers 10 99.84 Very High Very High Very High
Disease 33 99.32 Very High Very High Very High
Hypoglycemia 21 98.80 Very High Very High Very High
Syndrome 21 97.20 Very High Very High Very High
Aging 33 95.60 Very High Very High Very High
Cushing's Syndrome /

Hypercortisolism

2 95.08 Very High Very High Very High
Duodenal Ulcer 7 88.56 High High
Growth Problems 3 87.52 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Somatostatin release by antral and fundic mucosa of patients with pernicious anemia was also significantly decreased (20 +/- 8 pg/mg tissue, n = 12, and 7.6 +/- 2 pg/mg tissue, n = 12, respectively) (P less than 0.05).
Negative_regulation (decreased) of Localization (release) of Somatostatin associated with pernicious anemia and somatostatin
1) Confidence 0.59 Published 1988 Journal Scand. J. Gastroenterol. Section Abstract Doc Link 2902682 Disease Relevance 0.57 Pain Relevance 0.41
Carbamazepine and phenytoin inhibit somatostatin release from dispersed cerebral cells in culture.
Negative_regulation (inhibit) of Localization (release) of somatostatin associated with somatostatin and carbamazepine
2) Confidence 0.59 Published 1991 Journal Ann. Neurol. Section Title Doc Link 1681780 Disease Relevance 0 Pain Relevance 0.74
Phenytoin, another anticonvulsant with many similar properties, also blocked picrotoxin-induced somatostatin release at a concentration of 10(-4) M, and its effects were also reversed by veratridine at a concentration of 10(-5) M.
Negative_regulation (blocked) of Localization (release) of somatostatin associated with somatostatin and anticonvulsant
3) Confidence 0.59 Published 1991 Journal Ann. Neurol. Section Abstract Doc Link 1681780 Disease Relevance 0 Pain Relevance 0.87
Concentrations of carbamazepine within the therapeutic range (4 x 10(-5) M) inhibited spontaneous release of somatostatin and blocked secretory responses to the epileptogen, picrotoxin, and to the cyclic cAMP stimulator forskolin.
Negative_regulation (inhibited) of Localization (release) of somatostatin associated with somatostatin and carbamazepine
4) Confidence 0.59 Published 1991 Journal Ann. Neurol. Section Abstract Doc Link 1681780 Disease Relevance 0 Pain Relevance 0.67
Compounds thought to inhibit hypothalamic somatostatin (SRIH) release (pyridostigmine, arginine, galanin, atenolol) consistently improve, though do not normalize, the somatotropin response to GHRH in obesity.
Negative_regulation (inhibit) of Localization (release) of somatostatin associated with obesity and somatostatin
5) Confidence 0.57 Published 1999 Journal Int. J. Obes. Relat. Metab. Disord. Section Abstract Doc Link 10193871 Disease Relevance 0.57 Pain Relevance 0.19
These results imply possible impairments of the paracrine release of somatostatin in peptic ulcer disease and in pernicious anemia.
Spec (possible) Negative_regulation (impairments) of Localization (release) of somatostatin associated with pernicious anemia, peptic ulcer disease, somatostatin and disease
6) Confidence 0.43 Published 1988 Journal Scand. J. Gastroenterol. Section Abstract Doc Link 2902682 Disease Relevance 0.84 Pain Relevance 0.42
The beta3-adrenoceptor agonist GW427353 (Solabegron) decreases excitability of human enteric neurons via release of somatostatin.
Negative_regulation (decreases) of Localization (release) of somatostatin in neurons associated with somatostatin and agonist
7) Confidence 0.42 Published 2010 Journal Gastroenterology Section Title Doc Link 19786030 Disease Relevance 0.10 Pain Relevance 0.29
CONCLUSIONS: Inhibitory action of GW427353 involves release of SST which stimulates inhibitory SST2 receptors on human submucous neurons.
Negative_regulation (inhibitory) of Localization (receptors) of SST2 in neurons
8) Confidence 0.42 Published 2010 Journal Gastroenterology Section Body Doc Link 19786030 Disease Relevance 0 Pain Relevance 0
Since the GHRH-(1-29)NH2 dose (100 micrograms) used was a maximally stimulatory one, these results suggest that the enhancing effect of G-DAMME on GHRH-induced GH release may be mediated through inhibition of somatostatin release.
Negative_regulation (inhibition) of Localization (release) of somatostatin associated with somatostatin
9) Confidence 0.42 Published 1989 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 2546963 Disease Relevance 0 Pain Relevance 0.28
Our results indicate that 5-HT1D receptors have a stimulatory effect on GH secretion, possibly by inhibiting hypothalamic somatostatin release.
Negative_regulation (inhibiting) of Localization (release) of somatostatin associated with somatostatin
10) Confidence 0.42 Published 1995 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 7775648 Disease Relevance 0.07 Pain Relevance 0.60
These data suggest that the inhibitory effect of glucocorticoid excess on GH release is due to increased hypothalamic somatostatin secretion which appears to be dependent on DEX-induced enhanced beta-adrenergic responsiveness.
Negative_regulation (effect) of Localization (secretion) of somatostatin associated with somatostatin
11) Confidence 0.42 Published 1993 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 8094392 Disease Relevance 0 Pain Relevance 0.17
Since in our study G-DAMME was able to partially overcome the inhibitory effect of hGH administration, it is suggested that opioids act through an inhibition of somatostatin release and not through a GHRH-dependent pathway.
Negative_regulation (inhibition) of Localization (release) of somatostatin associated with somatostatin and opioid
12) Confidence 0.42 Published 1996 Journal Eur. J. Endocrinol. Section Abstract Doc Link 8590960 Disease Relevance 0 Pain Relevance 0.31
The latter result may provide a cellular basis for impairment in the paracrine release of fundic somatostatin in peptic ulcer disease.
Negative_regulation (impairment) of Localization (release) of somatostatin associated with peptic ulcer disease, somatostatin and disease
13) Confidence 0.42 Published 1991 Journal Gastroenterology Section Abstract Doc Link 2019362 Disease Relevance 0.55 Pain Relevance 0.15
It can be hypothesized that clonidine does not elicit GH secretion decreasing hypothalamic somatostatin tone.
Negative_regulation (decreasing) of Localization (secretion) of somatostatin associated with somatostatin and clonidine
14) Confidence 0.42 Published 1992 Journal Horm. Metab. Res. Section Abstract Doc Link 1398465 Disease Relevance 0.07 Pain Relevance 0.61
Glucocorticoids are thought to inhibit growth hormone (GH) secretion through an enhancement of endogenous somatostatin tone.
Negative_regulation (inhibit) of Localization (secretion) of somatostatin associated with somatostatin
15) Confidence 0.42 Published 1992 Journal Horm. Metab. Res. Section Abstract Doc Link 1398465 Disease Relevance 0.08 Pain Relevance 0.32
They further suggest a defect in the release of pituitary GH secondary to an abnormality in alternative neurotransmitter pathways resulting in decreased GHRH and/or increased somatostatin secretion.
Negative_regulation (decreased) of Localization (secretion) of somatostatin in pituitary associated with neurotransmitter and somatostatin
16) Confidence 0.41 Published 1986 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 3018032 Disease Relevance 0 Pain Relevance 0.28
The impairment of GH release after clonidine in obese subjects might be in a reduced serotonin release or in a failure of the hypothalamic-pituitary system to stimulate plasma GH caused by a diminished GH releasing factor stimulatory effect or by an excessive endorphin or somatostatin secretion in obesity.
Negative_regulation (diminished) of Localization (secretion) of somatostatin in plasma associated with obesity, somatostatin, serotonin and clonidine
17) Confidence 0.41 Published 1988 Journal Exp. Clin. Endocrinol. Section Abstract Doc Link 3243343 Disease Relevance 0.63 Pain Relevance 0.70
In all these data indicate that in the infant rat 1) GAL is a potent GH secretagogue; 2) the action of GAL is not exerted directly on GHRF- or somatostatin-secreting structures, but requires the intervention of catecholaminergic neurons; 3) the GH-releasing effect of GAL is ultimately exerted via GHRF release, although a mechanism operating to inhibit hypothalamic somatostatin release cannot be ruled out; and 4) differently from GAL, CLO releases GH via postsynaptic stimulation of GHRF-secreting neurons.
Negative_regulation (inhibit) of Localization (release) of somatostatin in neurons associated with somatostatin and clonidine
18) Confidence 0.41 Published 1988 Journal Endocrinology Section Abstract Doc Link 2449342 Disease Relevance 0.08 Pain Relevance 0.59
Somatostatin secretion is a direct effect of acid on the somatostatin cell, since it is unaffected by the axonal blocker tetrodotoxin.
Negative_regulation (effect) of Localization (secretion) of Somatostatin associated with tetrodotoxin and somatostatin
19) Confidence 0.37 Published 1986 Journal Scand. J. Gastroenterol. Suppl. Section Abstract Doc Link 2876506 Disease Relevance 0.13 Pain Relevance 0.71
Alpha 2-adrenergic agonism enhances the growth hormone (GH) response to GH-releasing hormone through an inhibition of hypothalamic somatostatin release in normal men.
Negative_regulation (inhibition) of Localization (release) of somatostatin associated with somatostatin
20) Confidence 0.33 Published 1990 Journal J. Clin. Endocrinol. Metab. Section Title Doc Link 1977761 Disease Relevance 0 Pain Relevance 0.49

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox